SciELO - Scientific Electronic Library Online

 
vol.53 número3Micetismos: Parte 4: Síndromes tempranos con síntomas complejos índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

  • No hay articulos citadosCitado por SciELO

Links relacionados

Compartir


Acta bioquímica clínica latinoamericana

versión impresa ISSN 0325-2957versión On-line ISSN 1851-6114

Resumen

COSTANTINI, Martín Hernán et al. Butirato de sodio como agente coadyuvante de la acción radioprotectora de la amifostina. Acta bioquím. clín. latinoam. [online]. 2019, vol.53, n.3, pp.397-408. ISSN 0325-2957.

Among the few radioprotectors in use, amifostine is effective in reducing the acute toxicity induced by ionizing radiation. However, it has important toxic effects that prevent its repeated use or in high doses. It is necessary then to develop less toxic radioprotectors, by themselves or as adjuvants of amifostine in low doses. Sprague-Dawley rats were exposed to an X-ray dose of 6 Gy (whole body). Sodium butyrate was tested as a mitigant after a low dose of amifostine prior to irradiation. At different times after the irradiation, the erythrocytes, leukocytes and the leukocyte formula were counted. Genotoxic effects were evaluated in blood leukocytes by the Comet assay. Sixty-day survival studies and histological evaluation of the duodenum and large intestine were also performed. The effect of the treatment was moderately protective with respect to the recovery of the normal values of erythrocytes, leukocytes and the leukocyte formula in the surviving animals in both sexes as well as for the intestinal epithelia and leukocytes DNA. It also significantly increased the 60-day survival. The radioprotection with amifostine in a low dose followed by mitigation with butyrate was clearly significant.

Palabras clave : Radioprotection; Sodium butyrate; Amifostine; WR-2721; X radiation.

        · resumen en Español | Portugués     · texto en Español     · Español ( pdf )

 

Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons